Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Catalyst-driven biotech momentum: Q2 revenue was $256.1M, up 32% YoY, EPS beat by a wide margin, LIFYORLI contributed $47.6M in its first quarter, and relacorilant NDA was resubmitted to the FDA. Shares are up about 33% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Low leverage ⢠Premium valuation CORT has strong liquidity, low leverage, and solid cash generation, but its sharply elevated valuation, no dividend, and high stock-based compensation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support defended ⢠Weak momentum Support Level: $110.00â$111.00 Resistance Level: $113.88 CORT is weakening after a volatile last month, with $110 support and $113.88 resistance key to confirming either stabilization or further downside.
Sentiment & News
Key News Insights: ⢠BlackRock stake ⢠Bullish coverage ⢠Earnings dip Corcept drew major institutional buying and bullish growth support despite modest post-earnings weakness.
AI Summary
Corcept's strong Korlym-driven cash generation and LIFYORLI launch make it a credible multi-product growth platform, but its premium valuation already prices in substantial relacorilant approval and commercialization successâmaking FDA outcomes and launch adoption the decisive catalysts for investors.
Description
Corcept Therapeutics is a U.S.-based biopharmaceutical company that discovers, develops and commercializes drugs for severe metabolic, oncologic and neuropsychiatric conditions. It markets Korlym (mifepristone) for hyperglycemia secondary to endogenous Cushingâs syndrome in adults with type 2 diabetes or glucose intolerance who have not had successful surgery or are ineligible, and has clinical-stage programs including relacorilant for Cushingâs and combination studies with nab-paclitaxel in advanced ovarian tumors, alongside separate programs targeting prostate cancer, antipsychotic-induced weight gain and FKBP5-related diagnostics. Founded in 1998, the company is headquartered in Menlo Park, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 30 | Aug 6 | CORT | Corcept Therapeutics Incorporated | Catalyst-driven biotech momentum: Q2 revenue was $256.1M, up 32% YoY, EPS beat by a wide margin, LIFYORLI contributed $47.6M in its first quarter, and relacorilant NDA was resubmitted to the FDA. Shares are up about 33% over 21 trading days. | Closed | -8.8% |
| Jun 8 | Jun 15 | CORT | Corcept Therapeutics Incorporated | Event-driven biotech momentum: shares are up about 42% over 21 trading days, Corcept raised 2026 revenue guidance, plans to resubmit the relacorilant NDA in Cushing's syndrome, and recent clinical updates keep the catalyst calendar active. | Closed | +13.4% |